Skip to main content

Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage

Project description

A vaccine against ALS

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that leads to loss of muscle control. Recent evidence indicates that a GGGGCC hexanucleotide repeat in the non-coding region of the C9orf72 gene is the most common genetic cause of ALS. This causes the formation of poly-glycine-alanine (poly-GA) aggregates in the brain cells responsible for ALS pathology. The EU-funded GA-VAX project aims to develop a poly-GA peptide vaccine as a treatment against ALS. Following encouraging preclinical results, researchers will develop a clinical vaccine and undertake all necessary toxicology and efficacy studies prior to conducting a clinical trial in ALS patients.

Coordinator

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Net EU contribution
€ 1 049 816,25
Address
Venusberg-campus 1/99
53127 Bonn
Germany

See on map

Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Research Organisations
Other funding
€ 0,00

Participants (1)

INTRAVACC BV
Netherlands
Net EU contribution
€ 1 449 993,75
Address
Antonie Van Leeuwenhoeklaan 9
3721 MA Bilthoven

See on map

Region
West-Nederland Utrecht Utrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00